296 related articles for article (PubMed ID: 27461138)
1. Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer.
Bakrania AK; Variya BC; Patel SS
Pharmacol Res; 2016 Sep; 111():577-591. PubMed ID: 27461138
[TBL] [Abstract][Full Text] [Related]
2. Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.
Schettini F; Giuliano M; De Placido S; Arpino G
Cancer Treat Rev; 2016 Nov; 50():129-141. PubMed ID: 27665540
[TBL] [Abstract][Full Text] [Related]
3. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
[TBL] [Abstract][Full Text] [Related]
4. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
[TBL] [Abstract][Full Text] [Related]
5. DEAE-Dextran coated paclitaxel nanoparticles act as multifunctional nano system for intranuclear delivery to triple negative breast cancer through VEGF and NOTCH1 inhibition.
Bakrania AK; Variya BC; Rathod LV; Patel SS
Eur J Pharm Biopharm; 2018 Jan; 122():37-48. PubMed ID: 29031923
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting the proliferation, migration and invasion of triple negative breast cancer cells through anti-tumor human serum albumin nanoparticles loading aziditaxel as a novel taxane derivative.
Chen LQ; Zhang ZM; Huang W; Gao ZG; Fang WS; Jin MJ; Yu L
Pharmazie; 2017 Mar; 72(3):152-160. PubMed ID: 29442050
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation.
Ravar F; Saadat E; Gholami M; Dehghankelishadi P; Mahdavi M; Azami S; Dorkoosh FA
J Control Release; 2016 May; 229():10-22. PubMed ID: 26968799
[TBL] [Abstract][Full Text] [Related]
8. Combined chemotherapy for triple negative breast cancer treatment by paclitaxel and niclosamide nanocrystals loaded thermosensitive hydrogel.
Zhao D; Hu C; Fu Q; Lv H
Eur J Pharm Sci; 2021 Dec; 167():105992. PubMed ID: 34517104
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
10. The role of taxanes in triple-negative breast cancer: literature review.
Mustacchi G; De Laurentiis M
Drug Des Devel Ther; 2015; 9():4303-18. PubMed ID: 26273192
[TBL] [Abstract][Full Text] [Related]
11. A review of the ligands and related targeting strategies for active targeting of paclitaxel to tumours.
Li J; Wang F; Sun D; Wang R
J Drug Target; 2016 Aug; 24(7):590-602. PubMed ID: 26878228
[TBL] [Abstract][Full Text] [Related]
12. Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment.
Bourgeois-Daigneault MC; St-Germain LE; Roy DG; Pelin A; Aitken AS; Arulanandam R; Falls T; Garcia V; Diallo JS; Bell JC
Breast Cancer Res; 2016 Aug; 18(1):83. PubMed ID: 27503504
[TBL] [Abstract][Full Text] [Related]
13. Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches.
Ghosh S; Javia A; Shetty S; Bardoliwala D; Maiti K; Banerjee S; Khopade A; Misra A; Sawant K; Bhowmick S
J Control Release; 2021 Sep; 337():27-58. PubMed ID: 34273417
[TBL] [Abstract][Full Text] [Related]
14. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
15. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
Lasham A; Mehta SY; Fitzgerald SJ; Woolley AG; Hearn JI; Hurley DG; Ruza I; Algie M; Shelling AN; Braithwaite AW; Print CG
Int J Cancer; 2016 Sep; 139(5):1157-70. PubMed ID: 27072400
[TBL] [Abstract][Full Text] [Related]
16. B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy.
Cheng N; Bei Y; Song Y; Zhang W; Xu L; Zhang W; Yang N; Bai X; Shu Y; Shen P
Biochem Pharmacol; 2021 Jan; 183():114298. PubMed ID: 33153969
[TBL] [Abstract][Full Text] [Related]
17. A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer.
Jain V; Kumar H; Anod HV; Chand P; Gupta NV; Dey S; Kesharwani SS
J Control Release; 2020 Oct; 326():628-647. PubMed ID: 32653502
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS-STING Signaling in Triple-Negative Breast Cancer.
Hu Y; Manasrah BK; McGregor SM; Lera RF; Norman RX; Tucker JB; Scribano CM; Yan RE; Humayun M; Wisinski KB; Tevaarwerk AJ; O'Regan RM; Wilke LG; Weaver BA; Beebe DJ; Jin N; Burkard ME
Mol Cancer Ther; 2021 Dec; 20(12):2553-2567. PubMed ID: 34583980
[TBL] [Abstract][Full Text] [Related]
19. Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy.
Guo S; Vieweger M; Zhang K; Yin H; Wang H; Li X; Li S; Hu S; Sparreboom A; Evers BM; Dong Y; Chiu W; Guo P
Nat Commun; 2020 Feb; 11(1):972. PubMed ID: 32080195
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
Allard B; Turcotte M; Stagg J
Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
